BioCentury
ARTICLE | Distillery Therapeutics

Cancer

May 3, 2018 4:17 PM UTC

Mouse studies suggest the PPARγ agonist Avandia rosiglitazone could help treat melanoma. In a mouse model of melanoma, Avandia plus an irradiated GM-CSF-secreting tumor cell vaccine and an anti-CTLA-4 mAb decreased tumor incidence and frequency of tumor ulceration and increased mouse survival compared with the vaccine plus anti-CTLA-4 mAb. Next steps by Novartis AG could include evaluating the Avandia-vaccine-mAb combination in other models of melanoma.

GlaxoSmithKline plc markets Avandia for Type II diabetes...